Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-pr07
Abstract: Background: Neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) are locally invasive tumors that can cause debilitating complications including pain, disfigurement, and functional limitations. The primary treatment option is surgical debulking, which is often challenging and… read more here.
Keywords: neurofibromatosis type; mek; plexiform neurofibromas; nf1 inoperable ... See more keywords